drugset / Trial / NCT01520077

Vytorin in the Treatment of Alopecia Areata

NCT01520077

Phase 1 Completed 29 enrolled University of Miami
NaSingle-groupOpen-labelTreatment

Summary

Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth. The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory process may help in permitting hair regrowth in those subjects.

Timeline

Start
2011-07
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 40 mg Oral
Subject Simvastatin Small molecule 10 mg Oral

Indications